For decades, the story of Alzheimer's research has been dominated by a battle between A-beta and tau amyloids, both of which ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.